Key facts
- TheraRNA’s last known valuation is $27.9M (Dec 2022).
- It has raised $6.4M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Oriental Fortune Capital, Shenzhen Weltrust Investment Co., CrowdBees, Share Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for TheraRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for TheraRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TheraRNA
Manufacturer of mRNA vaccine drugs designed to treat infectious diseases and cancers. The company offers proprietary lipid nanoparticle delivery technology and scalable mRNA production capabilities, enabling pharmaceutical companies, healthcare providers and research institutions to deliver affordable and effective vaccines to patients.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2019
- Employees
- 4
- Website
- therarna.cn/
- Ownership
- Privately Held (backing)
TheraRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TheraRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TheraRNA in its N-PORT filings yet. We sweep new filings monthly.